Freeline Therapeutics FRLN Stock
6.48 USD
{{ price }}
0.000000%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqCM
Market Cap
28.24M USD
LOW - HIGH [24H]
0.0000
-
0.0000 USD
VOLUME [24H]
0 USD
{{ volume }}
P/E Ratio
0
Earnings per share
0 USD
Freeline Therapeutics Price Chart
Freeline Therapeutics FRLN Financial and Trading Overview
| Freeline Therapeutics stock price | 6.48 USD |
| Previous Close | 2.66 USD |
| Open | 2.69 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 2.56 - 2.73 USD |
| 52 Week Range | 2.11 - 16.8 USD |
| Volume | 17.45K USD |
| Avg. Volume | 104.94K USD |
| Market Cap | 11.47M USD |
| Beta (5Y Monthly) | 0.514361 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.25 USD |
FRLN Valuation Measures
| Enterprise Value | -38472216 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.50704414 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.20494181 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.454 |
Trading Information
Freeline Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.514361 |
| 52-Week Change | -79.27% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 16.8 USD |
| 52 Week Low | 2.11 USD |
| 50-Day Moving Average | 4.11 USD |
| 200-Day Moving Average | 7.89 USD |
FRLN Share Statistics
| Avg. Volume (3 month) | 104.94K USD |
| Avg. Daily Volume (10-Days) | 35.84K USD |
| Shares Outstanding | 4.34M |
| Float | 1.19M |
| Short Ratio | 0.1 |
| % Held by Insiders | N/A |
| % Held by Institutions | N/A |
| Shares Short | 28.63K |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 0.66% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -38.81% |
| Return on Equity (ttm) | -69.97% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -84667000 USD |
| Net Income Avi to Common (ttm) | -61073000 USD |
| Diluted EPS (ttm) | -14.56 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 55.42M USD |
| Total Cash Per Share (mrq) | 12.76 USD |
| Total Debt (mrq) | 5.39M USD |
| Total Debt/Equity (mrq) | 9.63 USD |
| Current Ratio (mrq) | 2.809 |
| Book Value Per Share (mrq) | 12.89 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -70081000 USD |
| Levered Free Cash Flow (ttm) | -51745876 USD |
Profile of Freeline Therapeutics
| Country | United States |
| State | N/A |
| City | Stevenage |
| Address | Sycamore House |
| ZIP | SG1 2BP |
| Phone | 44 14 3890 6870 |
| Website | https://www.freeline.life |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 152 |
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Q&A For Freeline Therapeutics Stock
What is a current FRLN stock price?
Freeline Therapeutics FRLN stock price today per share is 6.48 USD.
How to purchase Freeline Therapeutics stock?
You can buy FRLN shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Freeline Therapeutics?
The stock symbol or ticker of Freeline Therapeutics is FRLN.
Which industry does the Freeline Therapeutics company belong to?
The Freeline Therapeutics industry is Biotechnology.
How many shares does Freeline Therapeutics have in circulation?
The max supply of Freeline Therapeutics shares is 4.36M.
What is Freeline Therapeutics Price to Earnings Ratio (PE Ratio)?
Freeline Therapeutics PE Ratio is 0.00000000 now.
What was Freeline Therapeutics earnings per share over the trailing 12 months (TTM)?
Freeline Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Freeline Therapeutics company belong to?
The Freeline Therapeutics sector is Healthcare.
Freeline Therapeutics FRLN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}